H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with ...

Fintel reports that on April 10, 2025, HC Wainwright & Co. downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) ...

H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $32 from $29 and keeps a Buy rating on the shares. The firm says the ...

H.C. Wainwright lowered the firm’s price target on Transcode Therapeutics (RNAZ) to $10 from $20 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on April 11, 2025, HC Wainwright & Co. initiated coverage of Richtech Robotics (NasdaqCM:RR) with a Buy ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to the asset.,The event adheres to common market appraisal procedures.,Within ...

Evolus, Inc. (NASDAQ:EOLS – Free Report) – Investment analysts at HC Wainwright dropped their FY2025 earnings per share estimates for Evolus in a report released on Thursday, April 10th.

HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15).

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of Bionano Genomics (LSE:0A4K) with a Buy recommendation. There are 12 funds or institutions reporting positions in ...